Chennai Journal

Helicobacter Pylori Infections Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Helicobacter Pylori Infections Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

September 30
21:21 2020
Helicobacter Pylori Infections Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

“Helicobacter Pylori Infections – Market Insights, Epidemiology, and Market Forecast-2030”

(Albany, US) DelveInsight has launched a new report on “Helicobacter Pylori Infections – Market Insights, Epidemiology, and Market Forecast-2030”.

 

DelveInsight’s “Helicobacter Pylori Infections – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Helicobacter Pylori Infections, historical and forecasted epidemiology as well as the Helicobacter Pylori Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the facts:

  • A study titled “Epidemiology of Helicobacter pylori in an Asymptomatic Population in the United States,” conducted by David et al., showed that the prevalence of H. pylori infection increased rapidly with age at one percent per year for the overall population.
  • The study by Sitas et al., titled “Helicobacter pylori infection rates in relation to age and social class in a population of Welsh men,” estimates that overall prevalence of H. pylori was 56.9%, increasing sharply in middle age from 29.8% in those aged 30–34 to over 59% in those aged 45 or older.
  • As per the study titled “A 5-year trend of Helicobacter pylori seroprevalence among dyspeptic patients at Bahir Dar Felege Hiwot Referral Hospital, Northwest Ethiopia” conducted by Meseret et al., the seroprevalence of H. pylori was significantly higher in males (43.2%) than in females (39.9%).
  • As per the study conducted by Campbell et al. (2005), approximately 0.5% of the UK population (around 290 thousand people, 20% of all general practice workload) are on long-term acid suppression because of peptic ulcer-related diseases which are attributable to chronic H. pylori infection.
  • According to Everhart et al., the prevalence of H. pylori is higher in Hispanics, African Americans, and the elderly. Its prevalence is 60% in Hispanics, 54% in African Americans, and 20% in Whites. The estimated prevalence is 20% for people younger than 30 years and 50% for those older than 60 years in the United States.

 

Request for free sample report: https://www.delveinsight.com/sample-request/helicobacter-pylori-h-pylori-infection-market

 

Scope of the Report

  • The report covers the descriptive overview of Helicobacter Pylori Infections, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Helicobacter Pylori Infections epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Helicobacter Pylori Infections are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Helicobacter Pylori Infections market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Helicobacter Pylori Infections market

 

Helicobacter Pylori Infections is a common type of bacteria that grows in the digestive tract and has a tendency to attack the stomach lining. It infects the stomachs of roughly 60 percent of the world’s adult population. H. pylori infections are usually harmless, but they’re responsible for the majority of ulcers in the stomach and small intestine. The “H” in the name is short for Helicobacter. “Helico” means spiral, which indicates that the bacteria are spiral shaped.

Symptoms

The symptoms associated with Helicobacter Pylori Infections include:

  • An ache or burning pain in abdomen
  • Abdominal pain that’s worse when the stomach is empty
  • Nausea
  • Loss of appetite
  • Frequent burping
  • Bloating
  • Unintentional weight loss

 

Request for free sample report: https://www.delveinsight.com/sample-request/helicobacter-pylori-h-pylori-infection-market

 

Causes

It’s still not known exactly how H. pylori infections spread. The bacteria have coexisted with humans for many thousands of years. The infections are thought to spread from one person’s mouth to another. They may also be transferred from feces to the mouth. This can happen when a person does not wash their hands thoroughly after using the bathroom. H. pylori can also spread through contact with contaminated water or food.

 

Complications

H. pylori infections can lead to peptic ulcers, but the infection or the ulcer itself can lead to more serious complications.

These include:

  • Internal bleeding, which can happen when a peptic ulcer breaks through the blood vessel and is associated with iron Deficiency anemia
  • Obstruction, which can happen when something like a tumor blocks the food from leaving the stomach
  • Perforation, which can happen when an ulcer breaks through the stomach wall
  • Peritonitis, which is an infection of the peritoneum, or the lining of the abdominal cavity

Treatment

Lowering stomach acid helps the antibiotics work more effectively. This treatment is sometimes referred to astriple therapy. Some of the drugs that are used in a triple therapy treatment include: clarithromycin, proton-pump inhibitors (PPI), such as lansoprazole (Prevacid), esomeprazole (Nexium), pantoprazole (Protonix), or rabeprazole (AcipHex), metronidazole (for 7 to 14 days), amoxicillin (for 7 to 14 days).

 

Request for free sample report: https://www.delveinsight.com/sample-request/helicobacter-pylori-h-pylori-infection-market

 

Some of the Companies:

  • Phathom Pharmaceuticals
  • Sequella
  • CJ Healthcare
  • Imevax
  • Crestone
  • And Many Others

Drugs Covered:

  • Vonoprazan
  • SQ 109
  • Tegoprazan
  • IMX 101
  • CRS3123

And Many Others

Table of Contents:

1. Key Insights

2. Executive Summary of Helicobacter Pylori Infections

3. Competitive Intelligence Analysis for Helicobacter Pylori Infections

4. Helicobacter Pylori Infections: Market Overview at a Glance

4.1. Helicobacter Pylori Infections Total Market Share (%) Distribution in 2017

4.2. Helicobacter Pylori Infections Total Market Share (%) Distribution in 2030

5. Helicobacter Pylori Infections: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Helicobacter Pylori Infections Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Helicobacter Pylori Infections Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Helicobacter Pylori Infections Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Helicobacter Pylori Infections Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Helicobacter Pylori Infections Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Helicobacter Pylori Infections Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Helicobacter Pylori Infections Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Helicobacter Pylori Infections Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Helicobacter Pylori Infections Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Helicobacter Pylori Infections Treatment and Management

8.2. Helicobacter Pylori Infections Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Helicobacter Pylori Infections Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Helicobacter Pylori Infections: Seven Major Market Analysis

13.1. Key Findings

13.2. Helicobacter Pylori Infections Market Size in 7MM

13.3. Helicobacter Pylori Infections Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Helicobacter Pylori Infections Total Market Size in the United States

15.1.2. Helicobacter Pylori Infections Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Helicobacter Pylori Infections Total Market Size in Germany

15.3.2. Helicobacter Pylori Infections Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Helicobacter Pylori Infections Total Market Size in France

15.4.2. Helicobacter Pylori Infections Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Helicobacter Pylori Infections Total Market Size in Italy

15.5.2. Helicobacter Pylori Infections Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Helicobacter Pylori Infections Total Market Size in Spain

15.6.2. Helicobacter Pylori Infections Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Helicobacter Pylori Infections Total Market Size in the United Kingdom

15.7.2. Helicobacter Pylori Infections Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Helicobacter Pylori Infections Total Market Size in Japan

15.8.3. Helicobacter Pylori Infections Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Helicobacter Pylori Infections

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Request for Detailed TOC: https://www.delveinsight.com/sample-request/helicobacter-pylori-h-pylori-infection-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/helicobacter-pylori-h-pylori-infection-market

Related Articles